Dr. Stephen Cutler

  • sam patrick posted an article
    Lindsay Cobbs named to head KPIC at USC see more

    Compliments of Midlands Biz

    The Kennedy Pharmacy Innovation Center (KPIC) announced that James Lindsay Cobbs has been named chair for the center.

    In his role, Cobbs will focus on creating a regulatory affairs program for students in the College of Pharmacy, including classroom, cocurricular, experiential, and post-graduate opportunities, as well as supporting Nephron Pharmaceuticals in regulatory affairs.

    “My priorities will hone in on developing experiential training opportunities that will enable our students to build skills for both traditional and nontraditional pharmacy roles, developing key partnerships that can support training for our students and to identify ways that will make the College of Pharmacy stand light years apart from other colleges across the country,” says Cobbs.

    Cobbs brings a wide array of career experiences to KPIC, ranging from clinical pharmacy to global policy development in the pharmaceutical industry. After graduating from the UofSC College of Pharmacy in 1992, he launched his career as a staff pharmacist at Johns Hopkins Medical Center. After four years, he entered public service as a regulatory affairs professional at the U.S. Food and Drug Administration (FDA) where he served as regulatory project manager, special assistant and lead project manager in the Office of Compliance and later as associate director for regulatory affairs (ADRA) in the Office of Translational Sciences.

    Cobbs then transitioned to the corporate sector at Janssen Pharmaceuticals, a division of Johnson & Johnson as a policy lead in the Americas, Global Regulatory and Policy Intelligence Department. Cobbs later became the head of US Policy, Global Regulatory Policy and Intelligence for UCB (Union Chimique Belge translated as Union Chemical of Belgium), a multinational biopharmaceutical company headquartered in Brussels, Belgium.

    Cobbs says his various roles have led him to this next challenge. “My experience as a pharmacist at a major teaching institution, working as a public health servant, co-leading drug review teams for novel drug products, and regulatory policy and intelligence in the pharmaceutical industry have prepared me for this unique role,” he says.

    Patti Fabel, Pharm.D. and executive director of KPIC is looking forward to joining efforts with Cobbs. “Our faculty, staff, and students can learn a great deal from him due to his background, experience and skill set,” Fabel says. “He will broaden the scope of what KPIC can offer our students and alumni by developing a regulatory affairs program. I’m excited to see the impact he has on the center and college.”

    Dean Stephen J. Cutler says Cobbs is an exceedingly accomplished expert in pharmaceutical regulatory affairs. “His addition to our faculty will bring added depth and breadth to our educational program as we launch our college’s latest initiative, the Regulatory Affairs Academic Program,” Cutler adds. “This academic program will offer regulatory education to our pharmacy students, provide postgraduate education for residents and fellows, and give another educational track to our graduate program. Our partnership with Nephron Pharmaceuticals will afford us a working laboratory for the development of future pharmacists and scientists serving in regulatory affairs. We are thrilled that Lindsay Cobbs will shepherd this initiative for the College of Pharmacy.”

    Cobbs will begin his role on July 1, 2020.

  • sam patrick posted an article
    Monday Moment 5-4-2020 see more

    SCBIO's latest Monday Moment arrives amidst the COVID-19 storm to provide meaningful and inspiring information in 3 minutes or less. This week, enjoy an uplifting reminder from University of South Carolina College of Pharmacy Dean Stephen Cutler  saluting all those on the front lines of healthcare, plus helpful webinars, news on how SC is stepping up and the ever-popular 3 Great LinksClick here.

  • sam patrick posted an article
    5-year Phase II COBRE grant will result in more funding to support research conducted at USC see more

    The National Institutes of Health (NIH) has awarded the University of South Carolina a five-year grant totaling more than $11.2 million to support the COBRE Center for Targeted Therapeutics based at the College of Pharmacy. This is Phase II of the COBRE grant, and follows the five-year Phase I portion of the research grant, which concluded this year.

    The COBRE Center for Targeted Therapeutics (CTT) is directed by SmartState endowed chair and drug discovery and biomedical sciences professor Dr. Igor Roninson, an internationally-recognized researcher in cancer therapeutics.

    “Dr. Roninson is an exceedingly accomplished scientist and has been successful in navigating the transition of this Center from the Phase I stage to the Phase II, which is not an easy task.  Less than one-half of the Phase I COBREs are successfully converted into a Phase II program,” said Dr. Stephen J. Cutler, Dean of the College of Pharmacy. “Under the Phase I Center, Dr. Roninson has directed the advancement of young faculty members into independently funded scientists, supported the growth of a critical mass of investigators focused on the design and discovery of new therapeutic agents, and enhanced the development of new research cores at the University of South Carolina.  Under the Phase II Center grant from NIH, Dr. Roninson should be able to strengthen the Center for Targeted Therapeutics at the UofSC.”

    Dr. Roninson was awarded the five-year Phase II COBRE grant of $2,235,000 annually from the National Institutes of Health to support the CTT. This Center was created to attract and foster the professional development of talented junior scientists dedicated to research in the treatment of debilitating diseases and to develop the infrastructure for targeted therapeutic studies.

    “Dr. Roninson’s Phase I COBRE-CTT established a cadre of highly talented and successful junior faculty in the College of Pharmacy, College of Arts and Sciences, and the School of Medicine, whose research efforts focused on the discovery of new drug targets,” said Dr. Kim Creek, Associate Dean of Research at the College of Pharmacy. “The impact of the COBRE-CTT on research productivity at UofSC is substantial and far reaching. The Phase II award will provide funding for the COBRE-CTT for an additional five years and will support the hiring of additional junior faculty in the area of targeted therapeutics and allow for overall growth of this thriving Center.”

    The Center for Targeted Therapeutics includes three resource cores, including the Functional Genomics Core, the Drug Design and Synthesis Core and the Microscopy and Flow Cytometry Core. A core director is assigned to each of the research cores. These experts provide scientific advice in project development, along with technological support.

    For more information on the College of Pharmacy’s COBRE Center for Targeted Therapeutics, visit: https://tinyurl.com/yyy72s6c